BioSpace News Archive

Advances Body of Knowledge Around Metabolic Pathways and Cellular Targets

Lodo’s Informatics-Enabled Drug Discovery Platform Accesses the Vast Collections of Undiscovered Drug-Like Molecules Encoded in Microbial DNA

A new tool for analyzing tissue damage seen on MRI brain scans can detect with more than 70 percent accuracy early signs of cognitive decline, new research shows.

Zolgensma is the first gene therapy based on REGENXBIO’s NAV® Technology Platform approved by the FDA and other regulatory authorities

Exact Sciences Corp. announced that the company generated revenue of $408.4 million for the third quarter ended September 30, 2020, compared to $218.8 million for the same period of 2019.

Acorda Therapeutics, Inc. will host a conference call and webcast in conjunction with its third quarter 2020 update and financial results on Tuesday, November 3 at 4:30 p.m. ET.

MyVeeva for Doctors app makes it easy for HCPs to access the people and resources they need to better treat patients

Kala Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, announced that the U.S. Food and Drug Administration has approved EYSUVIS 0.25% for the short-term treatment of the signs and symptoms of dry eye disease.

Motor function improvements were observed for all three SRK-015 treatment cohorts in the primary efficacy endpoints (Hammersmith scale scores) at six-months; top-line data from the 12-month treatment period are anticipated in 2Q21

TAE Life Sciences, a biologically-targeted radiation therapy company developing a breakthrough, accelerator-based boron neutron capture therapy system, announced that it has entered into an agreement with National Center of Oncological Hadrontherapy to provide its Alphabeam™ Neutron System for the treatment of invasive, recurrent and difficult to treat cancers.